PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan

Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6

Source: Clinical Genitourinary Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research